FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016446817> ?p ?o ?g. }

• W2016446817 endingPage "3692" @default.
• W2016446817 startingPage "3683" @default.
• W2016446817 abstract "Treatment of adult Philadelphia chromosome-positive lymphocytic leukemia is rarely successful. We report here the effects of TZD18, a novel dual ligand specific for peroxisome proliferator-activated receptor α and γ (PPARα/γ) on Ph+ lymphocytic leukemia cell lines BV173, SD1, and SupB-15. Exposure of these cells to TZD18 resulted in growth inhibition in a dose- and time-dependent manner that was associated with G1 cell cycle arrest. This effect was much stronger than that mediated by the PPARγ ligand pioglitazone (PGZ), which also belongs to the thiazolidinediones (TZD) class of ligands. However, it may not be mediated through PPARγ or PPARα activation because antagonists of PPARγ and PPARα cannot reverse it. Study of the key regulators of cell cycle progression by Western blot analysis showed that the expression of the cyclin-dependent kinase inhibitor (CDKI) p27kip1, but not that of p21cip1, was enhanced, whereas that of c-Myc, cyclin E, cyclin D2, and cyclin-dependent kinases 2 and 4 (CDK-2 and CDK-4) was decreased when these cells were treated with TZD18 (10 or 20 μM). Therefore, the up-regulation of p27kip1 and the down-regulation of CDK-2 and CDK-4 may, at least in part, account for the G1 cell cycle arrest. Furthermore, a remarkable induction of apoptosis was observed in the cells treated with this dual ligand. No obvious alteration of bcl-2 protein level occurred, but bax was up-regulated in these TZD18-treated cells. Activation of caspase 8 and caspase 9 by TZD18 was also observed. Importantly, NF-κB DNA-binding activity was markedly decreased by the TZD18 treatment. In addition, TZD18 enhanced the growth inhibitory effect of imatinib, a specific tyrosine kinase inhibitor therapeutically used in the treatment of Ph+ leukemia. Overall, our findings strongly suggest that TZD18 may offer a new therapeutic approach to aid in the treatment of Ph+ lymphocytic leukemia." @default.
• W2016446817 created "2016-06-24" @default.
• W2016446817 creator A5035435039 @default.
• W2016446817 creator A5050454886 @default.
• W2016446817 creator A5051618213 @default.
• W2016446817 creator A5069389160 @default.
• W2016446817 creator A5073043527 @default.
• W2016446817 creator A5081716847 @default.
• W2016446817 creator A5085340844 @default.
• W2016446817 date "2006-05-01" @default.
• W2016446817 modified "2023-10-17" @default.
• W2016446817 title "Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18" @default.
• W2016446817 cites W120676909 @default.
• W2016446817 cites W1500830863 @default.
• W2016446817 cites W1567127662 @default.
• W2016446817 cites W1812573520 @default.
• W2016446817 cites W1966861485 @default.
• W2016446817 cites W1967134457 @default.
• W2016446817 cites W1967433108 @default.
• W2016446817 cites W1973557663 @default.
• W2016446817 cites W1975812232 @default.
• W2016446817 cites W1978256546 @default.
• W2016446817 cites W1981101682 @default.
• W2016446817 cites W1985125630 @default.
• W2016446817 cites W1986712005 @default.
• W2016446817 cites W1987098514 @default.
• W2016446817 cites W1989860697 @default.
• W2016446817 cites W1991886593 @default.
• W2016446817 cites W1993216157 @default.
• W2016446817 cites W2005484362 @default.
• W2016446817 cites W2005624571 @default.
• W2016446817 cites W2011409339 @default.
• W2016446817 cites W2014844101 @default.
• W2016446817 cites W2020286683 @default.
• W2016446817 cites W2022879391 @default.
• W2016446817 cites W2023829802 @default.
• W2016446817 cites W2030207960 @default.
• W2016446817 cites W2031694725 @default.
• W2016446817 cites W2035539313 @default.
• W2016446817 cites W2041242857 @default.
• W2016446817 cites W2041352419 @default.
• W2016446817 cites W2042200885 @default.
• W2016446817 cites W2045830771 @default.
• W2016446817 cites W2047591801 @default.
• W2016446817 cites W2047982128 @default.
• W2016446817 cites W2050717908 @default.
• W2016446817 cites W2054154194 @default.
• W2016446817 cites W2054308635 @default.
• W2016446817 cites W2054851194 @default.
• W2016446817 cites W2062243628 @default.
• W2016446817 cites W2063703251 @default.
• W2016446817 cites W2063767155 @default.
• W2016446817 cites W2064331238 @default.
• W2016446817 cites W2064618183 @default.
• W2016446817 cites W206748399 @default.
• W2016446817 cites W2069412024 @default.
• W2016446817 cites W2077945404 @default.
• W2016446817 cites W2081353268 @default.
• W2016446817 cites W2082597621 @default.
• W2016446817 cites W2089687829 @default.
• W2016446817 cites W2105441981 @default.
• W2016446817 cites W2110956835 @default.
• W2016446817 cites W2118986158 @default.
• W2016446817 cites W2120913071 @default.
• W2016446817 cites W2122375017 @default.
• W2016446817 cites W2123502494 @default.
• W2016446817 cites W2125344994 @default.
• W2016446817 cites W2131067167 @default.
• W2016446817 cites W2135599444 @default.
• W2016446817 cites W2137606231 @default.
• W2016446817 cites W2138018530 @default.
• W2016446817 cites W2143938651 @default.
• W2016446817 cites W2147921405 @default.
• W2016446817 cites W2148749467 @default.
• W2016446817 cites W2151892297 @default.
• W2016446817 cites W2152105216 @default.
• W2016446817 cites W2158008449 @default.
• W2016446817 cites W2164015929 @default.
• W2016446817 cites W2171518012 @default.
• W2016446817 cites W2173994006 @default.
• W2016446817 cites W2288906881 @default.
• W2016446817 cites W2327827282 @default.
• W2016446817 cites W2330214547 @default.
• W2016446817 cites W2332406512 @default.
• W2016446817 cites W2419040043 @default.
• W2016446817 cites W2470223656 @default.
• W2016446817 cites W4231336234 @default.
• W2016446817 cites W4297754410 @default.
• W2016446817 doi "https://doi.org/10.1182/blood-2005-05-2103" @default.
• W2016446817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16403907" @default.
• W2016446817 hasPublicationYear "2006" @default.
• W2016446817 type Work @default.
• W2016446817 sameAs 2016446817 @default.
• W2016446817 citedByCount "58" @default.
• W2016446817 countsByYear W20164468172012 @default.
• W2016446817 countsByYear W20164468172013 @default.
• W2016446817 countsByYear W20164468172014 @default.
• W2016446817 countsByYear W20164468172015 @default.

• next